How do you stop a failing treatment early, before it costs you patients and resources?
Phase IIA trial design is one of the most consequential decisions in early drug development, since it determines how quickly a sponsor can stop an ineffective treatment before committing further patients or budget.
Phase II clinical trials sit at a critical juncture in drug development, the point at which we decide whether a candidate treatment shows enough early evidence of activity to justify a large, expensive Phase III programme. Because of this, Phase II designs need to be both statistically rigorous and ethically efficient, allowing sponsors to stop early when a treatment is unlikely to succeed.
In this free webinar, Brian Fox, Research Statistician at nQuery, provides an overview of Phase II clinical trial design with a particular focus on adaptive and multi-stage designs.
These include Simon's Two-Stage Design, Simon's Admissible Designs, Bryant & Day's (1995) design, Litwin et al.'s (2007) design, and Lin & Shih's (2004) design.
Worked examples throughout illustrate how each design is applied in oncology and other early-phase settings.
Learning objectives of this webinar:
Phase IIA proof-of-concept trials exist to screen out ineffective treatments as early and efficiently as possible, so that resources and patients are directed toward the candidates most likely to succeed. Achieving this requires designs that build in interim looks and pre-specified stopping rules, rather than committing to a fixed sample size upfront.
Simon's Two-Stage Design has long been the workhorse of single-arm Phase II oncology trials, and its Admissible Designs extension gives trialists a spectrum of options to balance expected and maximum sample size. More recent extensions adapt this framework to toxicity, survival, and adaptive response endpoints.
Whether it's choosing between an optimal and a minimax design, jointly screening for response and toxicity, or incorporating progression-free survival, there is a clear need to tailor the two-stage framework to the specific demands of a Phase IIA trial.
1. Overview of Phase II Clinical Trials and Where Phase IIA Trial Design Fits
We begin by examining the role of Phase II within the wider development pathway:
- The bridge between first-in-human Phase I and confirmatory Phase III trials
- The split between Phase IIA (proof-of-concept) and Phase IIB (dose-finding)
- Why early stopping for futility is central to Phase IIA design
- Single-arm vs. controlled Phase II designs
- How screening decisions at this stage shape the rest of the development programme
This context sets the stage for understanding why multi-stage design is the natural fit for Phase IIA's screening role.
2. Design Considerations for Adaptive & Multi-Stage Phase IIA Trial Design
Effective Phase IIA design requires careful pre-specification of several key elements:
- Stage boundaries and interim stopping rules for futility
- Trade-offs between expected sample size and maximum sample size
- Choice of primary endpoint (response, toxicity, progression-free survival)
- Optimal vs. minimax design philosophies
- Extending the two-stage framework to more complex or adaptive endpoints
Getting these elements right at the design stage is what allows a Phase IIA trial to fulfil its purpose: screening candidates efficiently and ethically.
3. nQuery Practical Demonstrations
The webinar includes hands-on worked examples in nQuery, covering:
- Simon's Two-Stage Design (Optimal & Minimax)
- Simon's Admissible Designs
- Two-Stage Design for Response & Toxicity (Bryant & Day)
- Two-Stage Design for Progression-Free Survival (Litwin)
- Two-Stage Design for Adaptive Response (Lin & Shih)
We conclude with a comparison of the designs covered and practical guidance on how to select the most appropriate design for a given clinical scenario.
About nQuery
nQuery helps make your clinical trials faster, less costly and more successful.
It is an end-to-end platform covering Frequentist, Bayesian, and Adaptive designs with 1000+ sample size procedures.
nQuery Solutions
Sample Size & Power Calculations
Calculate for a Variety of frequentist and Bayesian Design
